Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 4;59(8):1424.
doi: 10.3390/medicina59081424.

Hypertrophic Cardiomyopathy: Genetic Foundations, Outcomes, Interconnections, and Their Modifiers

Affiliations
Review

Hypertrophic Cardiomyopathy: Genetic Foundations, Outcomes, Interconnections, and Their Modifiers

Mila Glavaški et al. Medicina (Kaunas). .

Abstract

Hypertrophic cardiomyopathy (HCM) is the most prevalent heritable cardiomyopathy. HCM is considered to be caused by mutations in cardiac sarcomeric protein genes. Recent research suggests that the genetic foundation of HCM is much more complex than originally postulated. The clinical presentations of HCM are very variable. Some mutation carriers remain asymptomatic, while others develop severe HCM, terminal heart failure, or sudden cardiac death. Heterogeneity regarding both genetic mutations and the clinical course of HCM hinders the establishment of universal genotype-phenotype correlations. However, some trends have been identified. The presence of a mutation in some genes encoding sarcomeric proteins is associated with earlier HCM onset, more severe left ventricular hypertrophy, and worse clinical outcomes. There is a diversity in the mechanisms implicated in the pathogenesis of HCM. They may be classified into groups, but they are interrelated. The lack of known supplementary elements that control the progression of HCM indicates that molecular mechanisms that exist between genotype and clinical presentations may be crucial. Secondary molecular changes in pathways implicated in HCM pathogenesis, post-translational protein modifications, and epigenetic factors affect HCM phenotypes. Cardiac loading conditions, exercise, hypertension, diet, alcohol consumption, microbial infection, obstructive sleep apnea, obesity, and environmental factors are non-molecular aspects that change the HCM phenotype. Many mechanisms are implicated in the course of HCM. They are mostly interconnected and contribute to some extent to final outcomes.

Keywords: comorbidities; environment; epigenetics; gene; genetics; genotype; hypertrophic cardiomyopathy; modifier; outcomes; phenotype.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Sarcomere. Schematic illustration of a sarcomere, showcasing the essential contractile proteins, actin, and myosin, along with the structural protein titin. Additionally, the inclusion of myosin-binding protein C is deliberate, as it plays a pivotal role in finely regulating the interactions between the thin and thick filaments.
Figure 2
Figure 2
Factors contributing to final HCM phenotype.

Similar articles

Cited by

References

    1. Geske J.B., Ommen S.R., Gersh B.J. Hypertrophic cardiomyopathy: Clinical update. JACC Heart Fail. 2018;6:364–375. doi: 10.1016/j.jchf.2018.02.010. - DOI - PubMed
    1. Zegkos T., Tziomalos G., Parcharidou D., Ntelios D., Papanastasiou C.A., Karagiannidis E., Gossios T., Rouskas P., Katranas S., Paraskevaidis S., et al. Validation of the new American College of Cardiology/American Heart Association Guidelines for the risk stratification of sudden cardiac death in a large Mediterranean cohort with Hypertrophic Cardiomyopathy. Hell. J. Cardiol. 2022;63:15–21. doi: 10.1016/j.hjc.2021.06.005. - DOI - PubMed
    1. Sabater-Molina M., Pérez-Sánchez I., Hernández del Rincón J.P., Gimeno J.R. Genetics of hypertrophic cardiomyopathy: A review of current state. Clin. Genet. 2018;93:3–14. doi: 10.1111/cge.13027. - DOI - PubMed
    1. Medical Masterclass contributors. Firth J. Cardiology: Hypertrophic cardiomyopathy. Clin. Med. 2019;19:61–63. - PMC - PubMed
    1. Cao Y., Zhang P.Y. Review of recent advances in the management of hypertrophic cardiomyopathy. Eur. Rev. Med. Pharmacol. Sci. 2017;21:5207–5210. - PubMed